Eric Venker

ROIV President Eric Venker sells 200,000 shares at $30.27; scheduled 10b5-1 plan. Holds 1.61M post-sale.

Eric Venker, President & Immunovant CEO, sold 200,000 shares at $30.27 on 2026-05-22 as part of a pre-arranged 10b5-1 trading plan. This is a scheduled, non-discretionary transaction. His holding dropped from 1.81M to 1.61M shares (-11.0% vs pre-transaction holdings). The company is unprofitable with annual revenue growth of -71.6%, though the stock trades within its 52-week range at $29.96 current price. Prior same-ticker sales at ROIV show mixed 30/90-day post-sale price performance (ranging from +0.2% to +22.3% over 30 days), and cross-ticker selling history averaged 90-day returns of +31.3%. The scheduled nature of this transaction limits inference about insider sentiment; it reflects pre-planned execution rather than discretionary decision-making.

Venker (Immunovant CEO) sold 200,000 ROIV shares at $29.59; holds 1.65M post-sale amid revenue collapse

Venker Eric, President & Immunovant CEO, sold 200,000 shares (200.0K shares) at $29.59 on 2026-04-20 for $5,918,000.00 total value, reducing his holdings by 10.8% to 1,647,546 shares. His prior trades at ROIV show mixed timing outcomes—at the 90-day mark, 0 of 3 measurable prior sales were well-timed (stock rallied after each), averaging +24.1% over 90 days. The sale occurs within the 52-week range and 2.3% below the 52-week high, but the company fundamentals are deeply stressed: annual revenue contracted 76.7% to $2.0M quarterly revenue, and the firm posted a net loss of $-265.9M over its most recent full fiscal year. The timing relative to documented insider behavior suggests this sale follows a pattern of selling into strength—the 30-day change is +4.4%, yet his cross-ticker track record shows a 0.00% well-timed selling rate, indicating his prior sales across all tickers did not anticipate declines. The substantial loss position and collapsed revenue growth warrant monitoring for potential strategic capital needs or conviction shifts, though the sale's execution during a positive price-momentum window is consistent with his historical pattern.

ROIV CEO Venker sold 200.0K shares at $28.24 for $5.6M, reducing stake by 10.8% amid -76.7% revenue decline

Venker Eric, ROIV CEO, sold 200,000 shares (200.0K shares) at $28.24 on 2026-03-17, reducing his holdings from 1.85M shares to 1.65M shares (-10.8%). The sale occurred near the 52-week high of $29.72, at approximately 95% of peak valuation. Contextually, the company is facing severe operational headwinds: annual revenue declined -76.7% year-over-year to a reported $2.0M, and full-year net income was negative at $-265.9M, while market cap remains elevated at $19.9B relative to revenue base. Among his prior trades at ROIV specifically, only one measurable 90-day outcome is recorded (the 2025-12-09 sell returned +41.6% at 90 days), representing poor timing by the sell standard. The narrative does not indicate whether this sale was discretionary or scheduled under a trading plan.

CEO Eric Venker sells 200,000 shares of ROIV at $26.49; stock at 52-week high, company deeply unprofitable (-$265.9M net income).

Eric Venker, President & CEO, sold 200,000 shares (10.8% of his then-holdings) on 2026-02-13 at $26.49, reducing his position from 1.85M to 1.65M shares. The transaction occurred as ROIV traded near its 52-week high of $27.67 and has appreciated 35.6% over the prior 90 days and 18.8% over the prior 30 days. Notably, Venker's cross-ticker track record shows a 90-day well-timed rate of 0.00%, meaning his prior 20 sells across all tickers did not precede declines—the stock typically continued rising after his dispositions. At ROIV specifically, his 5 prior trades include one measurable 90-day outcome (November 2025 sale followed by +4.6% return), indicating the stock rose after that prior sale as well. Against this backdrop, the company is severely unprofitable (net income of $-265,891,000.00 for the most recent fiscal year) and posted only $1,999,000.00 in latest-quarter revenue alongside a -76.7% annual revenue decline, creating a structural tension between deteriorating fundamentals and elevated share price.

Venker (Immunovant CEO) sells 200,000 ROIV shares at $21.92; stock at $23.81 (52-week high); -76.7% revenue decline amid losses

Venker sold 200,000 shares for $4,384,000.00 at $21.92 on 2026-01-12, reducing holdings by -10.8% while ROIV traded near its 52-week high of $23.81. The sale occurred as the company faces severe operational headwinds: annual revenue fell -76.7%, latest quarterly revenue was $1,571,000.00 ($1.6M), and full-year net income was negative at $-113,519,000.00 ($-113.5M). Across his 5 prior trades at ROIV, none achieved well-timed sell outcomes at the 90-day measurement, though recent transactions (late December 2025) remain unmeasurable. The combination of substantial executive liquidation near a 52-week peak, alongside dramatic revenue contraction and deepening losses, signals material deterioration in the company's financial trajectory.

CEO Eric Venker sold 275,000 shares ($6.2M) at $22.45–$22.53; now holds 1.65M shares post-sale.

Eric Venker, President & CEO of Roivant Sciences (ROIV), executed 2 separate sales totaling 275,000 shares for $6,179,750.00 on consecutive trading days (2025-12-23 and 2025-12-24) at prices of $22.45 and $22.53, representing a -14.3% reduction in his pre-transaction holdings. This sale occurs at near the 52-week high ($22.94), with the stock currently trading at $21.70 and up 43.4% over 90 days. The company remains unprofitable with net income of $-113,519,000.00 in its latest quarterly period and faces severe revenue headwinds (-76.7% annual decline). Venker's cross-ticker track record shows a 90-day well-timed rate of 0.00% on 20 prior sells, and his prior 5 sales at ROIV (October–December 2025) have all been followed by positive 30-day returns (+3.7% to +19.8%), indicating a pattern of selling before continued upside rather than before declines.

Immunovant CEO Venker sells 200,000 ROIV shares at $20.85; post-sale holding 1,497,908 shares

Eric Venker, President and CEO of Immunovant (the largest shareholder in Roivant Sciences), sold 200,000 shares on 2025-12-09 at $20.85, reducing his stake from 1.70M to 1.50M shares (-11.8%). This represents a material reduction in exposure to ROIV at a price $0.49 below the current market price of $21.34. The timing context is significant: Venker's prior sales at ROIV (5 trades between October and November) occurred when the stock was in its early rally phase (+3.7% to +31.2% returns in 30 days post-trade), and the current sale occurs at the 52-week high of $21.34, yet the stock has still risen. Against this backdrop, Venker's recent selling pattern—beginning in mid-October and continuing through December—coincides with ROIV's 51.6% surge over 90 days and coincides with the company's severe revenue contraction (-76.7% annual decline) and persistent unprofitability (-$113.5M net loss in the latest quarter on just $1.6M quarterly revenue). The strategic timing of CEO share sales during periods of strong stock appreciation amid deteriorating fundamentals warrants investor scrutiny.

ROIV CEO Venker sells 200.0K shares at $20.22; stock at 52-week high ($20.62), revenue down 76.7% YoY, unprofitable.

Eric Venker, President & CEO of Immunovant, sold 200,000 shares (200.0K) of ROIV at $20.22 on 2025-11-07, reducing his holdings from 1.70M to 1.50M shares. The stock has rallied 28.6% over the past 30 days and 79.5% over 90 days, now trading at the 52-week high of $20.62. However, the company's fundamentals reveal material deterioration: quarterly revenue stands at $2.2M with an annual revenue decline of -76.7% YoY, and ROIV posted a net loss of $223.4M in its most recent full fiscal year. Venker has executed five separate sales at ROIV in October and early November, with the stock at the top of its 52-week range, while the company operates deeply unprofitable with collapsing revenue. The sale occurs in the context of strong recent price momentum but severe operational challenges.

ROIV CEO Venker sells 851,383 shares for $14.5M across 3 days as stock hits 52-week high of $17.26

President & Immunovant CEO Eric Venker executed 3 separate sales totaling 851,383 shares for $14,467,502.37 at prices between $16.93 and $17.06 over October 15–17, reducing his holdings by 36.1%. The sales occurred precisely as the stock reached its 52-week high of $17.26 (current price), having rallied +13.0% over 30 days and +50.9% over 90 days. Against this backdrop of sustained momentum, the company reported severe fundamental deterioration: quarterly revenue of $2,170,000.00 with a net loss of $223,355,000.00, and annual revenue decline of -76.7%. The concentrated liquidation of over one-third of his position at elevated prices while the business contracts sharply presents a material signal for investors to scrutinize the operational trajectory and management's confidence in near-term recovery.

Venker (ROIV CEO) sells 125.7K shares for $2.0M at $16.29–$16.30 amid +42.1% 90-day rally; company unprofitable with -76.7% revenue decline

Eric Venker, President & CEO of Immunovant at Roivant Sciences, executed 2 separate sales totaling 125,667 shares for $2,047,335.75 at a blended average price of $16.29, reducing his holdings by 7.7% to 1,504,959 shares. The sales occurred on 2025-10-09 and 2025-10-13 during a sharp rally—ROIV has gained 42.1% over 90 days and now trades at its 52-week high of $16.40. Against this backdrop, the company's fundamentals remain deeply troubled: latest-quarter revenue was $2,170,000.00, annual revenue contracted 76.7% year-over-year, and full-year net income was negative at $-223,355,000.00. Venker's cross-ticker track record shows a 90-day well-timed rate of 9.09% on 20 prior sells, but his recent trading pattern at ROIV (5 sells in 14 days, all with outcomes not yet measurable) occurs in a context of extreme valuation compression relative to operational deterioration—the $11.2B market cap sits atop mounting losses and collapsing revenues.